A NEW STANDARD OF CARE
Our mission at PreciseDx® is to deliver objective, accurate and reliable reporting of key clinical information within hours, to improve comprehensive decision-making for patients affected by cancer.
PreciseDx allows cancer specialists to confidently formulate a comprehensive review of their patient's specific tumor, allowing for a more informed care plan.
94%
Negative Predictive Value*
98%
Reproducibility and Repeatability**
99%
Intra-Lab Concordance**
*Fernandez, G., Prastawa, M., A.S. et al. Breast Cancer Research 2022
**PreciseDx's "Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer", Clinical Breast Cancer, Nov 2023
The science
We’ve long known that the secrets of cancer can be seen directly in their cellular structure, but in the past we could only look at that structure qualitatively. PreciseDx changes that.
PreciseBreast™ uses OncoIntelligence™ , our proprietary AI-platform, to combine 7 morphologic features with 4 clinical factors to produce a single OncoIntelligence Score™ between 0 and 100.
PreciseBreast™, clinically validated in more than 3,000 breast cancer cases1,2,3, accurately and reliably stratifies patients into two cohorts based on risk of disease recurrence at 6 years.
Low risk patients have, on average, a 6% recurrence risk, while high risk patients have, on average, a 24% recurrence risk.
1) Gerardo Fernandez et al, 2022. Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years. Breast Cancer Research, 24(1), pp.1-11.
2) Physicians from MCI ordered the 21-gene assay for prospective clinical treatment decisions 6 years ago. This cohort represents the same patients’ stored H&E-stained glass slides that were then tested with PreciseBreast to report predicted prognostic outcomes. As reported at SABCS 2024, outcome data has been kept for these patients to match with test scores.
3) Specimen was collected from the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital, the Netherlands on patients that were prospectively tested with the 70-gene assay for prospective clinical treatment decisions 6 years ago. This cohort represents the same patients’ stored H&E-stained glass slides that were then tested with PreciseBreast to report predicted prognostic outcomes. As reported at ESMO 2024, outcome data has been kept for these patients to match with test scores.
Jun 18, 2025
Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™
See More
Jun 18, 2025
Funding now totals over $43 million, strengthened leadership focused on a 2026 commercial launch of the OncoIntelligence™-driven, PreciseBreast™
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Contact us today to learn more about PreciseBreast.